Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-LSR monoclonal antibody 16-6
- Development stage
- Preclinical
- Lead developer
- Osaka Medical Center for Cancer and Cardiovascular Diseases
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-LSR monoclonal antibody 16-6 is a monoclonal antibody biologic that targets the lipolysis-stimulated lipoprotein receptor (LSR). LSR is a protein involved in the formation of tricellular tight junctions and is frequently overexpressed in epithelial ovarian cancer (EOC), where its expression correlates with poor prognosis. The 16-6 antibody specifically binds to LSR-expressing cells and is rapidly internalized and trafficked to lysosomes. This property has been leveraged in preclinical research to develop an antibody-drug conjugate (ADC) by linking the 16-6 antibody to the cytotoxic payload monomethyl auristatin E (MMAE). The resulting LSR-ADC has demonstrated potent antitumor activity in LSR-positive EOC cell lines and xenograft models. The development of this antibody is primarily associated with the Osaka International Cancer Institute and other Japanese research institutions.
- Other names
- anti-LSR mAb 16-6
02
Targets
LSR (Lipolysis-stimulated lipoprotein receptor)
Beyond the preview
Go deeper on anti-LSR monoclonal antibody 16-6.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-LSR monoclonal antibody 16-6.